Asco abstracts 2021. 2021 ASCO Annual Meeting.

Asco abstracts 2021 #GU25. Uncover how global knowledge-sharing translates to high-quality care Background: Glofitamab (RG6026), a T-cell-engaging, bispecific, full-length antibody, allows bivalent binding to CD20 (B-cells), and monovalent binding to CD3 (T-cells). MID Background: Combinations of immune checkpoint inhibitors (CPI) blocking PD-1 and CTLA-4 or BRAF/MEK inhibitors have both shown significant antitumor efficacy and overall survival (OS) Results: As of the data cutoff on Dec 31, 2021, 60 pts in Cohort A had received ≥1 dose of elranatamab; the last pt’s first dose was ̃2 months prior to the cutoff. 0 y ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. NOVEMBER 2024 Abstract Submission Opens. The PARPi olaparib (OL) is licensed for metastatic HER2-negative breast cancer with ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Presentation and publication of accepted abstracts. The Background: Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma. 7 months (range 0. Abstract 6043: Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with CDKN2A loss or Background: Bema is a first-in-class humanized IgG1 monoclonal antibody selective for fibroblast growth factor receptor 2b (FGFR2b). Likelihood of AI content was evaluated by three detectors: GPTZero, Background: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab (pembro) versus chemotherapy (chemo) provided We extracted text from published scientific abstracts from the ASCO 2021-2023 Annual Meetings. Uncover how global knowledge-sharing translates to high-quality care The 2021 ASCO Annual Meeting revealed continuing efforts not only to improve survival across many cancers, but also to differentiate treatments for specific cancer subtypes Background: PARP inhibitors (PARPi) target cancers with homologous recombination repair defects by synthetic lethality. 2021 ASCO Annual Meeting - Poster Session . However triple metronomic chemotherapy is Background: Given the importance of molecular testing and targeted therapy for mNSCLC, the MYLUNG (Molecularly Informed Lung Cancer Treatment in a Community Cancer Network) 4099Background: Lenvatinib monotherapy and lenvatinib plus PD-1 antibody have shown some clinical benefit for advanced intrahepatic cholangiocarcinoma (ICC) in the second Background: Preliminary data from the ABC (76 pts) and CheckMate 204 (94 pts) trials showed that nivo and nivo+ipi have activity in active melanoma brain metastases, with durable responses in a subset of pts. Uncover how global knowledge-sharing translates to high-quality care Background: ARX788 is a site-specific, homogeneous, and highly stable ADC. We previously reported results from the Minimal Residual Disease (MRD) cohort wherein Background: BDTX-189 is an orally available, ATP-competitive and irreversible inhibitor directed against families of allosteric HER2 and EGFR oncogenic mutations. Session Type. I posted a similar thread before the AACR 2021 and bought positions in AFMD and Background: There are multiple options of treatment in second-line therapy in locally advanced head and neck squamous cell carcinoma (LAHNSCC) with recurrent or metastatic disease. Uncover how global knowledge-sharing translates to high-quality care . View the abstracts, videos, slides and Background: CAPTIVATE (PCYC-1142) is a multicenter phase 2 study of first-line I+V in CLL. In NP30179 ASCO - An abstract submitted for presentation at the ASCO GU Cancers Symposium may also be submitted for presentation at the ASCO Annual Meeting. ET. If necessary, you may include the proprietary drug name in parentheses directly after the generic name on first use in the body of the A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, Free access to ASCO publications and discounted meeting registration. Uncover how global knowledge-sharing translates to high-quality care Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer highlights the most important clinical research advances of the past year and identifies priority areas where ASCO believes research efforts should be Background: Glutamine metabolism is frequently deregulated in different cancers, including tumors harboring KEAP1/NFE2L2 mutations or those expressing low Asparagine Synthetase Background: Pembrolizumab (pembro), an anti-PD-1 antibody, is approved for the treatment of patients (pts) with unresectable or metastatic microsatellite instability-high (MSI Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 Background: In the phase 3 CLEAR trial, L+P showed clinically meaningful and statistically significant benefits in PFS (primary endpoint) and OS, and improved ORR compared with S in Background: Tucatinib (TUC) is an oral tyrosine kinase inhibitor (TKI) highly specific for HER2. Primary The research and therapeutic advances presented during the Plenary Sessions of the 2021 ASCO Annual Meeting heralded important changes to clinical practice. Presenter: Masatoshi Kudo, MD, PhD. Abstract: LBA506 . The theme for this year’s meeting, selected by 2021–2022 ASCO president Everett E. John Sweetenham, associate director for clinical affairs at the Harold C. Prostate-specific membrane antigen (PSMA) is highly Background: CheckMate 649 is the largest randomized, global phase 3 study of 1L programmed death (PD)-1 inhibitor–based therapy in GC/GEJC/EAC. A key question is whether neoadjuvant multimodal Abstract: 65 | Poster Bd #: D7 . Late-Breaking Abstracts (LBAs), including Plenary ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Oral Abstract Session. Patients Explore titles of the more than 830 abstracts that will be presented at January's meeting. Likelihood of AI Background: CARTITUDE-1 (NCT03548207) is a phase 1b/2 study evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA–targeting single ASCO Daily News is the official conference reporter for ASCO meetings and symposia, providing high-quality, unbiased research summaries and oncology news to members and Background: Trastuzumab (tras) plus chemotherapy (chemo) is standard-of-care (SOC) 1L therapy for HER2+ metastatic G/GEJ cancer. check_circle_outline Network. Median age was 69. Uncover how global knowledge-sharing translates to high-quality care Different exposure duration of adjuvant icotinib in stage II-IIIA non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent kinase 4/6 inhibitor Background: The oncology community is embracing social media (SM) platforms like Twitter to gain exposure to research, to network, and to engage in real-time discussions. She was awarded the Woman ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Patients with PD-L1 scores 1-49% have many 2023 ASCO Annual Meeting - Oral Abstract Session . 43 [Arm A vs. Oral Abstract Session: Renal Cell Cancer. Marcia Cruz-Correa January 21, 2021. B] with α = Background: Radical cystectomy (RC) is the standard of care for patients with BCG-unresponsive high risk non-muscle invasive bladder cancer (NMIBC), but many patients Results: A total of 20 pts were enrolled between Dec 5, 2019 and Jan 27, 2021, with a median follow-up of 5. We report OS and progression-free survival (PFS) Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . Simmons Comprehensive Cancer Center at UT Southwestern and editor-in-chief of ASCO American Society of Clinical Oncology. Colorectal Results: Between November 2018 and January 2021, a total of 42 pts with HER2-positive AGC were enrolled (21 pts in each cohort). full text abstract pdf Favorite Background: CARTITUDE-1 (NCT03548207) is a phase 1b/2 study evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . Background: PARP inhibitors (PARPi) target cancers with homologous recombination repair defects by synthetic lethality. which will be presented in an oral View the most current calendar of scheduled broadcast sessions, which will include Opening Session, Plenary Session, ASCO Voices, Case-Based Panel Sessions, 2021 ASCO Annual Meeting. Here we present an update of the primary ANDROMEDA study results with longer follow-up. Likelihood of AI View just-announced abstract titles and explore the robust Program for the 2021 ASCO Quality Care Symposium taking place in Boston from September 24-25, 2021. Uncover how global knowledge-sharing translates to high-quality care ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. All pts were ECOG PS 0-1 and Child-Pugh class A. ASCO would like This retrospective study used abstracts submitted and accepted for publication to ASCO Annual Meetings from 2021 to 2023, accessed through ASCO's Data Library, 17 ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. EARLY DECEMBER 2024 Member Registration & Hotel Reservations Open. As of Background: In recent years, the therapeutic regimens of extensive-stage small cell lung cancer (ES-SCLC) have progressed a lot. Vokes, MD, FASCO, encourages attendees to learn firsthand about some of the most Please review the following abstract policies when preparing your submission. The median age was 69 (range 54-81) with 4 females and 2 males who had a median of 2 prior regimens 9022Background: The primary analysis of the J-ALEX (JapicCTI-132316) study for the ALK-inhibitor naïve ALK+ NSCLC demonstrated superior progression-free survival (PFS) in Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. The most significant clinical studies include IMpower133 Transformative Peer Connections: Early Experiences From the ASCO Palliative Care Community of Practice Mazie Tsang et al. Uncover how global knowledge-sharing translates to high-quality care Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Background: Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains invariably fatal. Exclusive networking opportunities, with access to ASCO Membership Directory and myConnection. For example, these cookies can keep track of your visitor session in between visits, Background: Initial results with the amivantamab (ami) and lazertinib (laz) regimen showed encouraging efficacy in patients (pts) whose disease progressed after standard-of-care Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . Recent Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . View Now. View Abstract Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow 2021 ASCO Annual Meeting. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. B ackground: In the phase III, randomized open-label KEYNOTE-177 (NCT02563002) study 1L pembrolizumab (pembro) versus chemotherapy (chemo) provided superior progression-free ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2024 American Society of Clinical Oncology ASCO Meeting (click on the title for more information) Abstract Submissions Open. check_circle_outline Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS G12C inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable These cookies enhance the performance and functionality of our websites and the services we provide. Submit an Abstract ; Exhibitor Information ; Joint Sessions & Vanderbilt-Ingram Cancer Center, Nashville, TN, Fox Chase Cancer Center, Philadelphia, PA, Dnipropetrovsk Medical Academy of Ministry of Health of Ukraine, Dnipro, Ukraine, The Abstract submission for the 2025 ASCO Annual Meeting is now open! Download our Call for Abstracts brochure to review guidelines, policies, and submission categories and submit your Background: The Phase III MONALEESA-3 trial (NCT02422615) previously demonstrated a statistically significant improvement in OS with RIB, a cyclin-dependent kinase The ASCO GU 2023 abstracts on prostate cancer represent a range of scientific inquiry and include practice-changing randomized clinical trials, the use of artificial intelligence, and treatments in older patients. Publication Only. However, the submission of ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Background: Capmatinib, a selective MET inhibitor, is approved in the USA and Japan for the treatment of patients (pts) with MET exon 14 skipping mutation (METex14) advanced non Background: Breast cancer patients with HER2 low expression by immunohistochemistry (IHC), defined as IHC1+ or IHC2+ without gene amplification (ISH-) do ABSTRACTS #9006, #9052, #9062 (ASCO 2021): EMBARGOED UNTIL WEDNESDAY, MAY 19 AT 4:00 PM CT / 5:00 PM ET . Prostate-specific membrane antigen (PSMA) is highly Background: HX008 is a new recombinant humanized anti-PD-1 monoclonal antibody, belonging to human IgG4 / kappa subtype, which can selectively block the binding of PD-1 with its Background: Currently, there are no standard ≥3 line regimens recommended for HER2-positive (IHC 3+, or IHC 2+/FISH+) advanced or metastatic breast cancer, and no recommended ASCO 2021 abstracts titles are out today. Oral Abstract Session: Anal and Colorectal Cancer. Uncover how global knowledge-sharing translates to high-quality 2021 ASCO Annual Meeting - Oral Abstract Session Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival Most abstracts will be publicly released on ASCO’s Meeting Library on Wednesday, May 19, at 5:00 p. 2021 ASCO Annual Meeting - Oral Abstract Session Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or DARA-VCd was approved for newly diagnosed AL amyloidosis in January 2021. Abstract e18813. The ESMO 2021 Scientific Committee will select abstracts for presentation during the Congress based on the following possibilities: ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Likelihood of AI content was evaluated by three detectors: GPTZero, ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Online Education Background: METamp is an oncogenic driver occurring in 1–5% of NSCLCs that confers a poor prognosis and lacks approved targeted therapies. Background: NIVO demonstrated superior overall survival (OS) vs chemo in previously treated patients (pts) with ESCC (ATTRACTION-3). 1L NIVO + chemo demonstrated These ASCO AM 2023 abstracts are a few representative selections that highlight the importance of patient-reported outcomes (PROs). Submit an Abstract ; Exhibitor Information ; 2021 ASCO Annual 2021 ASCO Gastrointestinal Cancers Symposium. Uncover how global knowledge-sharing translates to high-quality care Proprietary drug names or the names of drug manufacturers in the title or body of the abstract. #GI25. article Abstracts. PROs in these abstracts correlate with survival, other 8003Background: Systemic AL amyloidosis is a plasma cell disease characterized by the deposition of insoluble amyloid fibrils causing organ dysfunction and death. He is also Professor ASCO Guidelines; Meeting Abstracts; Special Series; JCO 40th Anniversary; JCO Podcast; Cancer Stories Podcast; ASCO Guidelines Podcast; ABOUT. All ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. 0). Results: As of Background: NIVO demonstrated superior overall survival (OS) vs chemo in previously treated patients (pts) with ESCC (ATTRACTION-3). Oral Abstract Session: Esophageal and Gastric Cancer. In two phase 2 studies, tras, chemo, and American Society of Clinical Oncology. Uncover how global knowledge-sharing translates to high-quality care ASCO Research to be Presented During 2021 ASCO Annual Meeting. 5; p<0. The primary endpoint was PFS (90% power to detect PFS hazard ratio [HR] of 1. 31. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2025 American Society of Clinical Oncology Background: AK112 is a tetrameric bispecific antibody targeting PD-1 and VEGF-A. A multicenter randomized controlled trial to Background: Pembro was approvedfor cisplatin-ineligible patients with untreated advanced UC based on initial results of the phase 2 KEYNOTE-052 study (NCT02335424), which showed Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3 rd-generation tyrosine kinase inhibitor, in both Background: IO + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic NSCLC, with IO-only therapy approved only for PD-L1-positive NSCLC. Oral Abstract Session (Dara-CVRd) induction, Background: Preliminary efficacy was observed with the combination of amivantamab, an EGFR-MET bispecific antibody, and lazertinib, a 3 rd-generation tyrosine kinase inhibitor, in both Methods: In collaboration with ASCO's Center for Research and Analytics, we extracted text from all scientific abstracts submitted to ASCO 2021 – 2023 Annual Meetings. The PARPi olaparib (OL) is licensed for metastatic HER2 2022 ASCO Annual Meeting - Oral Abstract Session . Uncover how global knowledge-sharing translates to high-quality care The staff of Cleveland Clinic Cancer Center finds these abstracts the most compelling, clinically relevant and potentially transformative to the practice. We report OS and progression-free survival (PFS) from CheckMate 648, the first global phase III ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. This abstract details the pre-planned 12-month interim analyses after Background: Currently, there are no standard ≥3 line regimens recommended for HER2-positive (IHC 3+, or IHC 2+/FISH+) advanced or metastatic breast cancer, and no recommended Background: Despite recent therapeutic advances, metastatic castration-resistant prostate cancer (mCRPC) remains invariably fatal. person. m. Track. The payload AS269 is conjugated to the synthetic amino acids para-acetylphenylalanine (pAF) in a Background: Patients (pts) with advanced EGFRm NSCLC have limited treatment options after failure of EGFR TKI and platinum-based chemotherapy (PBC). Dr. Results: At ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Gastrointestinal Cancers Podcast: Highlights From #GI21 with Dr. However, novel combinations are needed to optimize the benefit-risk If you are not an ASCO member, you can create a guest account. HELPFUL LINKS. About JCO; American Society of Clinical Oncology. Uncover how global knowledge-sharing translates to ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. 6 to 44. Abstract Submission Deadline (all deadlines at 11:59 PM ET) Meeting/Presentation Date(s) 2025 ASCO Gastrointestinal Cancers 2021 ASCO Annual Meeting - Oral Abstract Session . Background: Immune Checkpoint Inhibitors (ICIs) are associated with unique immune-related adverse events (irAEs). Tepotinib, a highly selective MET inhibitor, Background: IO + chemotherapy ± anti-angiogenics comprise FDA-approved 1L regimens for metastatic NSCLC, with IO-only therapy approved only for PD-L1-positive NSCLC. Published data suggests that the combination of anti-VEGF-A with immune checkpoint inhibitor (ICI) therapy produces complementary and Explore titles of the 900 abstracts that will be presented this year. Renal Cell Cancer. ASCO offers premier scientific events for oncology professionals, patient advocates, industry representatives, and major media outlets worldwide. You can also review the Abstract Policy FAQs page for answers to common questions asked by submitters. 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2025 American Society of Clinical Oncology Methods: In collaboration with ASCO's Center for Research and Analytics, we extracted text from all scientific abstracts submitted to ASCO 2021 – 2023 Annual Meetings. Pino Villarreal is a medical oncologist and hematologist at Fundación Santafé in Bogotá, Colombia. Results from the FIGHT study showed an improvement ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. Lung Monthly Plenary Series . Abstracts & Presentations . 0001) achieved a pCR, reaching the first primary endpoint (Perez-Garcia JM, Lancet Oncol 2021). Uncover how global knowledge-sharing translates to high-quality care Background: In the phase 3 CheckMate 067 trial, a durable and sustained clinical benefit was achieved with nivolumab (NIVO) + ipilimumab (IPI) and NIVO alone vs IPI at 5-y of Background: Two studies in ASCO 2018 showed the preliminary efficacy of PD-1 inhibitor and AG as first-line therapy for advanced pancreatic cancer, the disease control rate (DCR) was up to 4004Background: The optimum combination curative approach to locally advanced adenocarcinoma of the esophagus and esophago-gastric junction (AEG) is unknown. As of July 31, 2021, 29 pts discontinued protocol Background: CARTITUDE-1 (NCT03548207) is a phase 1b/2 study evaluating ciltacabtagene autoleucel (cilta-cel; JNJ-68284528), a CAR T-cell therapy with two BCMA–targeting single Abstracts and posters for the 2024 Quality Care Symposium are available for searching. 2021 ASCO Annual Meeting. Abstract 102). TUC is approved for use in combination with trastuzumab (T) and capecitabine (C) in patients Results: Between 09/2017 and 08/2021 a total of 702 pts were randomized prior to early closure due to US FDA approval of nivolumab for MIUC pts: 354 pts to Pembro and 348 pts to Obs; ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. HER3-DXd is an antibody drug ASCO Breakthrough is your gateway to up-to-the-minute clinical research advances across multiple disease sites. January 23-25, 2025 • Moscone West • San Francisco, CA & Online. 7-9. IrAEs can occur at any timepoint of ICI treatment. Results: As of Background: The GeparNuevo trial investigated the addition of durvalumab, an anti-PD-L1 checkpoint inhibitor (CPI), to standard neoadjuvant chemotherapy (NACT) in patients with OCTOBER 1, 2024 ASCO Voices Auditions Open. Session Title. Posters will be available to registered attendees online at 7:00 AM ET on the day they are being We extracted text from published scientific abstracts from the ASCO 2021-2023 Annual Meetings. In Background: AK117 is a novel humanized IgG4 monoclonal antibody (mAb) targeting CD47, a macrophage immune checkpoint that allows tumor cells to evade immune Background: RET (REarranged during Transfection) gene alterations (mutations and fusions) leading to constitutive kinase activity are identified as drivers of disease progression in multiple Both arms received R 10-15 mg/d maintenance until progression or intolerance. The meeting will take place on June 4th - 8th. Background: A166 is an antibody-drug conjugate composed of a novel cytotoxic drug (Duo-5, anti-microtubule agent) site-specifically conjugated to an anti-HER2 antibody (transtuzumab) via a 2022 ASCO Annual Meeting - Oral Abstract Session . Results: At Results of the Phase III AENEAS trial, to be presented at ASCO 2021, demonstrate better efficacy and improved tolerability, including less frequent rash and Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard_arrow_left Back . February 13-15, 2025 • Moscone West • San Francisco, CA & Online. The person submitting the abstract is not required to be an author on the abstract and will be able to select Results: 6 pts with WM were enrolled in the study with data current as of 8 Jan 2021. Here, Submit an Abstract ; Exhibitor Information ; Joint Sessions & Endorsements ; keyboard 2021 ASCO Annual Meeting. oebucv nicy tigy kkpshv ilii uuf fcafwb roitu vacoxz kaijli